Robotic-assisted radical prostatectomy: a multicenter experience with the Senhance Surgical System

Evaluation of Clinical Research on Novel Multiport Robotic Platforms for Urological Surgery According to the IDEAL Framework: A Systematic Review of the Literature

“…The remaining 59 studies included in our systematic review were noncomparative surgical series or case reports [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] .…”

“…Fifteen studies reporting clinical data for the Senhance surgical robotic system were included in our review [17] , [18] , [28] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] ( Table 5 ). Most studies evaluating the Senhance robot in urology have been focused on RARP.…”

“…A 2023 matched pair analysis (stage 3) by Lin et al [17] in Taiwan compared 63 RARPs performed with the Senhance robot to 63 da Vinci RARPs, which revealed no differences in EBL, postoperative complications, PSM rate, 3-mo undetectable PSA rate, or 3-mo urinary incontinence rate. Kulis et al [72] recently reported data for 375 RARPs performed in the context of a multicentre study. The authors reported a conversion rate of 5.3% and a postoperative complication rate of 3.4% for this larger series.…”

“…Although approved both in Europe in 2014 and in the USA in 2017, the Senhance robotic system has not been widely tested or used since then. The studies available were performed in Croatia and Lithuania, mainly for RARP; the larger explorative study included 375 cases [72] . A matched-pair analysis performed in Taiwan assessed Senhance RARP versus da Vinci RARP and demonstrated overlapping perioperative outcomes [17] .…”